Lucknow: Chronic Myeloid Leukemia (CML) — which forms a major share of adult blood cancer cases in Uttar Pradesh — can now be ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Alembic Pharma received USFDA approval for its generic Dasatinib Tablets (20–140 mg), equivalent to Sprycel by BMS. The drug ...

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...

Chronic Myeloid Leukaemia is a rare type of blood cancer which requires immediate medical attention However people are choosing to live without treatment but is this safe Let’s find out ...

The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dasatinib Tablets, ...

Detailed price information for Enliven Therapeutics Inc (ELVN-Q) from The Globe and Mail including charting and trades.